• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Imagyn starts sales of Site Select

Article

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site

Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site Select allows physicians to locate and extract a biopsy specimen in one step. When the device is used with a stereotactic table, biopsies can be done with local anesthesia on an outpatient basis.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Related Content
© 2024 MJH Life Sciences

All rights reserved.